NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

Search

Coloplast A-S (Class B)

Fechado

394.7 -0.58

Visão Geral

Variação de preço das ações

24h

Atual

Mín

390.6

Máximo

397.2

Indicadores-chave

By Trading Economics

Rendimento

522M

1.4B

Vendas

83M

7B

P/E

Médio do Setor

22.883

67.147

EPS

6.32

Rendimento de Dividendos

5.69

Margem de lucro

19.835

Funcionários

16,983

EBITDA

309M

2.3B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

5.69%

2.36%

Próximos Ganhos

12 de mai. de 2026

Próxima data de dividendos

20 de mai. de 2026

Próxima data de ex-dividendo

18 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-27B

91B

Abertura anterior

395.28

Fecho anterior

394.7

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 23:53 UTC

Ganhos

Naver Posts Weaker First-Quarter Earnings

29 de abr. de 2026, 23:41 UTC

Ações em Alta

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 de abr. de 2026, 23:55 UTC

Ganhos

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 de abr. de 2026, 23:54 UTC

Ganhos

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 de abr. de 2026, 23:52 UTC

Ganhos

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 de abr. de 2026, 23:51 UTC

Ganhos

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan 1Q Net CNY1.70B, Down 14%

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan: Power Generation Down 2.9% as of End-March

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss Narrows>000002.SZ

29 de abr. de 2026, 23:18 UTC

Ganhos

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 de abr. de 2026, 23:17 UTC

Ganhos

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 de abr. de 2026, 23:13 UTC

Ganhos

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 de abr. de 2026, 23:12 UTC

Ganhos

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 de abr. de 2026, 23:04 UTC

Ganhos

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 de abr. de 2026, 23:04 UTC

Ganhos

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat